GlaxoSmithKline Catches Heat With Fraud Charges
- Earnings Review: Growth May Be Hard To Come By But GM’s Sales Are At A Very High Level Right Now
- AMD Turns Profitable In Q2’16: Expected Growth In All Businesses To Help Deliver Non-GAAP Profitability In 2H’16
- Brexit Could Be Good Or Bad News For Jaguar Land Rover
- Vale’s Q2 2016 Production Review: Decline In Iron Ore Output As Production Cuts Take Effect
- Boeing Recognizes A $2.78 Billion Charge Ahead Of Q2 Earnings
- Recent Product Launches Drive Growth For Abbott Laboratories In Q2’16
The pharmaceutical industry has certainly been dramatic lately.
AstraZenaca spurned Pfizer for a third time, even after an eye-popping $117-billion proposal.
This time, Pfizer may not be coming back with a sweetened offer. The company has said it will focus on internal growth, as well as other potential deals.
Both sides are cooling down, but now things at GlaxoSmithKline (GSK.L) are heating up . . .
Once again, the UK drugmaker is in hot water, as it faces another criminal investigation, this time by Britain’s fraud office for alleged bribery.
This comes less than two weeks after Chinese officials alleged that GSK staff bribed officials, doctors and hospitals with a total of $480 million. Senior managers from GSK’s China business have been charged with corruption.
It’s the biggest scandal to hit a foreign company in China since 2009, and similar allegations are surfacing in Jordan, Lebanon, Iraq and Poland – indicating a pattern of behavior.
GSK argues that it has no systemic issue with unethical behavior. And in an attempt to move on, it’ll be rolling out a new sales model, under which it’ll become the first company in the industry to stop paying doctors to promote its products.
So, the allegations are almost assuredly hurting Glaxo’s reputation, but what about its shares?
Since news broke, GlaxoSmithKline’s American depositary receipts (ADRs), which trade under the ticker GSK, have dropped by over 4%.
GSK’s dividend yield is an attractive 4.7%, in an industry that’s fertile ground for dividend investors.
Pfizer and Novartis (NVS) pay dividends of 3.4% and 3.1%, respectively. Next in ranking, Merck’s (MRK) yield sits at 3.0%. Lastly, with dividend yields of 2.9% and 2.8%, respectively, there’s Roche (RHHBY) and Johnson & Johnson (JNJ).
As details of the scandal emerge, we’ll see if this mark on GSK’s report card will have a long-lasting effect.
Income Research Team